Saturday, July 19, 2025
LBNN
  • Business
  • Markets
  • Politics
  • Crypto
  • Finance
  • Energy
  • Technology
  • Taxes
  • Creator Economy
  • Wealth Management
  • Documentaries
No Result
View All Result
LBNN

Sumitomo Cuts 62 Jobs in NYC Due to Company Consolidation

Simon Osuji by Simon Osuji
July 6, 2023
in Technology
0
Sumitomo Cuts 62 Jobs in NYC Due to Company Consolidation
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Pictured: New York City skyline/iStock, StockByM

Pictured: New York City skyline/iStock, StockByM

Sumitomo Pharma America plans to lay off 62 employees from its New York City office previously owned by its subsidiary Sumitovant Biopharma, according to a WARN notice published July 3.

The company stated the layoffs are a result of its effort, previously announced in April, to combine its seven subsidiaries into one company dubbed Sumitomo Pharma America. The merger and name change went into effect on Saturday.

The July 3 filing is an amendment to a notice filed on April 20 that stated Sumitovant was cutting approximately 23 members of staff from the New York City office, effective July 20. In addition to the change in the total number of workers that will be laid off, the newest filing also pushed the layoff date for three employees to Oct. 5 and two others will now leave the company on July 31.

The merger includes seven subsidiaries in total: Sunovion Pharmaceuticals, Sumitomo Pharma America Holdings, Sumitomo Pharma Oncology, Sumitovant Biopharma, Myovant Sciences, Urovant Sciences and Enzyvant Therapeutics. Only one subsidiary, Spirovant Sciences, will continue to operate on its own, according to the April announcement.

Sumitomo stated the decision to merge the companies was spurred by the loss of exclusive rights for Latuda, which it called “one of the core products of the Sumitomo Pharma Group in the U.S.” According to Sumitomo’s 2022 financial report filed on June 27, total revenue for 2023 is forecasted to decrease by 119.7 billion yen (approximately $833.3 million) due to the “sheer magnitude of the loss of exclusivity for Latuda in the U.S.”

Latuda was previously owned by Sunovion Pharmaceuticals and is approved to treat schizophrenia and bipolar depression. The first generic versions of Latuda were launched on Feb. 20, 2023, by Accord Healthcare, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, MSN/Novadoz, Sun Pharmaceutical Industries, Alkem Laboratories/Ascend, Zydus Pharmaceuticals and Lupin Ltd.

Myovant Sciences, one of the subsidiaries that will be consolidated in the merger, was recently acquired by Sumitovant in March. The acquisition, announced in October 2022, was valued at approximately $1.7 billion.

Hiroshi Nomura, CEO of Sumitomo, stated the acquisition will best position the company to “accelerate the potential opportunities” for Orgovyx and Myfembree, for which Myovant had previously secured five regulatory approvals in the U.S. and Europe in hormone-sensitive oncology and women’s health, respectively.

Rosemary Scott is an editor at BioSpace, focusing on the job market and career development for professionals in the life sciences. You can reach her at rosemary.scott@biospace.com and on LinkedIn.

Source link

Related posts

Customs seizes 420kg Pangolin scales in Kano – EnviroNews

Customs seizes 420kg Pangolin scales in Kano – EnviroNews

July 19, 2025
Climate justice movements celebrate African leadership in rejecting solar geoengineering at AMCEN – EnviroNews

Climate justice movements celebrate African leadership in rejecting solar geoengineering at AMCEN – EnviroNews

July 19, 2025
Previous Post

Hands-on review: Imou Versa and Imou Cell Go security cameras

Next Post

“Rita Mawuena Benissan: Preserving Ghana’s Royal History

Next Post

"Rita Mawuena Benissan: Preserving Ghana's Royal History

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

Startups Weekly: Cutting through Google I/O noise

Startups Weekly: Cutting through Google I/O noise

2 months ago
Mozilla responds to backlash over new terms, saying it’s not using people’s data for AI

Mozilla responds to backlash over new terms, saying it’s not using people’s data for AI

5 months ago
Communications innovation could markedly improve AI training process

Communications innovation could markedly improve AI training process

1 week ago
What is it? Is it Free to Use?

What is it? Is it Free to Use?

2 years ago

POPULAR NEWS

  • Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    0 shares
    Share 0 Tweet 0
  • When Will SHIB Reach $1? Here’s What ChatGPT Says

    0 shares
    Share 0 Tweet 0
  • The world’s top 10 most valuable car brands in 2025

    0 shares
    Share 0 Tweet 0
  • Top 10 African countries with the highest GDP per capita in 2025

    0 shares
    Share 0 Tweet 0
  • Tanzania’s natural gas sector goes global with Dubai deal

    0 shares
    Share 0 Tweet 0
  • Privacy Policy
  • Contact

© 2023 LBNN - All rights reserved.

No Result
View All Result
  • Home
  • Business
  • Politics
  • Markets
  • Crypto
  • Economics
    • Manufacturing
    • Real Estate
    • Infrastructure
  • Finance
  • Energy
  • Creator Economy
  • Wealth Management
  • Taxes
  • Telecoms
  • Military & Defense
  • Careers
  • Technology
  • Artificial Intelligence
  • Investigative journalism
  • Art & Culture
  • Documentaries
  • Quizzes
    • Enneagram quiz
  • Newsletters
    • LBNN Newsletter
    • Divergent Capitalist

© 2023 LBNN - All rights reserved.